Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.67 |
| ▸ | MAOA | P21397 | 5/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | SDHA | P31040 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CALML3 | P27482 | 1/20 | 0.67 |
| ▸ | F10 | P00742 | 6/20 | 0.53 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323788 | 1.00 | MAOB (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL4173980 | 0.94 | MAOA (0.60) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL13945012 | 0.94 | MAOA (0.60) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL2089448 | 0.93 | MAOB (0.61) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL2089395 | 0.93 | MAOB (0.61) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7833227 | 0.91 | MAOA (0.61) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL10151500 | 0.91 | MAOA (0.63) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5725604 | 0.91 | MAOB (0.56) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5725608 | 0.91 | MAOB (0.56) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6229500 | 0.91 | MAOB (0.56) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124597-A1 | BORON CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2011037731-A1 | BORON CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011037731-A1 | BORON CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2007138381-A2 | PHOSPHONATED OXAZOLIDINONES AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS INC. (CA) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124597-A1 | BORON CONTAINING SMALL MOLECULES | BCL6B, BCL6, BLVRB | MAOB 1879/4885MAOA 4479/4885PTGS1 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.